---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-23-000091"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2023-08-30T23:59:59+00:00"
generated_at: "2026-06-11T02:08:09.135642+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# JNJ updates 2023 guidance post-Kenvue separation; raises sales & EPS outlook, cuts share count

## Summary
- Updated 2023 guidance: Reported Sales Growth 7.0%-8.0%, Adjusted EPS $10.00-$10.10 (12.5% growth at midpoint).
- Reduced share count by ~191M shares; partial-year benefit of ~73.5M shares adds $0.28 to EPS.
- Received $13.2B cash from Kenvue debt offering and IPO; retains 9.5% equity stake in Kenvue.
- Consumer Health now reported as discontinued ops; expects ~$20B gain in Q3 2023.
- Maintains quarterly dividend of $1.19/share; H1 2023 continuing ops sales $42.4B (+5.9% total).

## SEC filing metadata
- accession: 0000200406-23-000091
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2023-08-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040623000091/0000200406-23-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040623000091/jnj-20230830.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-23-000091
- JSON: https://secwatch.observer/filing/0000200406-23-000091.json
- Plain text: https://secwatch.observer/filing/0000200406-23-000091.txt

## Key facts
- Earnings Releases
  JOHNSON & JOHNSON updated its guidance (raised).
  - Guidance: raised
  - Result: guidance update
  source text: Johnson & Johnson completed an exchange offer to finalize the separation of Kenvue Inc. (the "Kenvue Separation"). On August 30, 2023, Johnson & Johnson issued the attached press release (Exhibit 99.1) providing updated financials and 2023 guidance following completion of the Kenvue Separation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/200406/000020040623000091/0000200406-23-000091-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.